TX-MOBIL-1/FORZA-MTRSPRT
Today, the Mobil 1 brand, the world's leading synthetic engine oil, announced its expanded collaboration with Forza Motorsport, the best-selling and most-awarded racing video game franchise, in which gamers and race fans around the world will be able to compete against professional motorsports drivers such as racing legend Tony Stewart and recent INDY NXT winner Jamie Chadwick. Beginning July 25, 2024, gamers and motorsports fans will have the unique opportunity to compete against these drivers on Maple Valley, a United States-themed, Mobil 1-branded, in-game track. Additional professional race car drivers will be announced later this year for gamers to compete against in upcoming Legend vs. Leaderboard Rival Events.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725776163/en/
Motorsports icons including Tony Stewart and Jamie Chadwick to race gamers in-game and on-track in Legend vs. Leaderboard Rival Events. (Graphic: Business Wire)
The collaboration continues the celebration of the Mobil 1 brand’s 50th anniversary through exclusive branded content, a chance to win incredible prizes, and the opportunity to beat iconic motorsports driver’s timed laps on the 4.81km virtual course. The Forza Motorsport collaboration marks the Mobil 1 brand’s largest campaign in the video game entertainment space and celebrates both the Mobil 1 team’s 50-year legacy and its longstanding passion for racing.
Kicking off the Legend vs. Leaderboard Rival Events is racing legend Tony Stewart, an American motorsports icon. From July 25 to August 7, 2024, gamers will have the chance to try to beat Stewart’s time on the Maple Valley virtual racetrack. Fans can also look forward to exclusive content on Mobil 1 Racing social media channels – part of a Legend vs. Leaderboard Rival Events social media series – showcasing Stewart setting his time to beat while driving a classic 1969 Ford Mustang Boss 302. New celebrity drivers will be featured in the content series throughout the remainder of 2024. Each month, a new legendary driver will take on the Maple Valley track, providing ongoing challenges, new prizes, and additional content for audiences to enjoy.
“We are thrilled to bring this iconic collaboration to life with Forza Motorsport to continue the celebration of the Mobil 1 brand's historic 50th anniversary,” said Laura Bustard, Global Brand Manager, on behalf of the Mobil 1 team. “This collaboration signifies our continued commitment to innovation and excellence in motorsports while also showcasing our passion for racing beyond a physical racetrack but increasingly in the virtual world. We are proud to have created a dynamic and immersive experience for gamers and race fans that allows us to celebrate our legacy, and we cannot wait to see fans share in the excitement by racing against a variety of professional motorsports drivers.”
Later this summer, the next Legends vs. Leaderboard Rivals Event series will take place and feature British racing driver Jamie Chadwick. From August 29 through September 11, 2024, gamers will have the opportunity to race against the rising motorsports star. Chadwick will be racing a 1967 Corvette as she invites the global Forza Motorsport audience to join her in-game for the chance to beat her timed lap.
Forza Motorsport, created by Turn 10 Studios and Xbox Game Studios, continues to be one of the premier racing games by giving players an opportunity to participate in racing events around a variety of both real and fictional tracks – including some of their favorite tracks – available in-game. As the Mobil 1 brand continues to grow within the gaming space and curate incredible experiences for driving enthusiasts, the Forza Motorsport relationship serves as a key milestone to reach new audiences and provide unique virtual automotive experiences – all while sharing its love of driving at a global level.
The Legends vs. Leaderboard Rival Events will kick off on July 25 and run through December 11, 2024 with five different events for gamers and race fans to participate in.
To stay up to date and learn more about this collaboration, visit https://promotions.mobil.com/offers/Mobil1Gaming-forza. Also, stay tuned for driver announcements and exclusive content on @Mobil1Racing on Instagram and X.
About Mobil 1
For 50 years, the Mobil 1 brand has been trusted by drivers to help keep their engines running longer. Our products combine the latest technology and innovation to exceed the toughest standards of vehicle manufacturers and tuning shops—so consumers can get the most out of their time behind the wheel, both on the road and on the track. Turn every day into an adventure with Mobil 1 products, the world’s leading synthetic motor oil brand. Learn more at www.mobil1.us or and follow @Mobil1Racing on Instagram and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240725776163/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom